Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Inhibikase Therapeutics (IKT) FCF Margin (2020 - 2023)

Inhibikase Therapeutics (IKT) has disclosed FCF Margin for 4 consecutive years, with 344243100.0% as the latest value for Q4 2023.

  • Quarterly FCF Margin fell 34423750523.0% to 344243100.0% in Q4 2023 from the year-ago period, while the trailing twelve-month figure was 1724492300.0% through Sep 2024, down 172448668417.0% year-over-year, with the annual reading at 6947.87% for FY2023, 730549.0% up from the prior year.
  • FCF Margin for Q4 2023 was 344243100.0% at Inhibikase Therapeutics, down from 5159.16% in the prior quarter.
  • The five-year high for FCF Margin was 200.41% in Q3 2020, with the low at 344243100.0% in Q4 2023.
  • Average FCF Margin over 4 years is 21539540.75%, with a median of 4540.49% recorded in 2023.
  • The sharpest move saw FCF Margin surged 20509540bps in 2022, then tumbled 2000000000bps in 2023.
  • Over 4 years, FCF Margin stood at 555.42% in 2020, then crashed by -37833bps to 210690.17% in 2021, then surged by 97bps to 5594.77% in 2022, then crashed by -6152840bps to 344243100.0% in 2023.
  • According to Business Quant data, FCF Margin over the past three periods came in at 344243100.0%, 5159.16%, and 3921.82% for Q4 2023, Q3 2023, and Q2 2023 respectively.